NEW YORK, September 24, 2015 /PRNewswire/ --
Equity Research Institute has initiated coverage on the
following equities: Celgene Corporation (NASDAQ: CELG), Ariad
Pharmaceuticals Inc. (NASDAQ: ARIA), ImmunoGen Inc. (NASDAQ: IMGN),
BioDelivery Sciences International Inc. (NASDAQ: BDSI), and
Esperion Therapeutics Inc. (NASDAQ: ESPR). Free research report on
Celgene can be accessed at https://www.erionline.net/CELG.pdf On
Wednesday, September 23, 2015, the
NASDAQ Composite ended at 4,752.74, down 0.08%, the Dow Jones
Industrial Average edged 0.31% lower, to finish the day at
16,279.89, and the S&P 500 closed at 1,938.76, down 0.20%. The
losses were broad based as all the sectors ended the session in
negative. Register for your complimentary reports at the links
given below.
Celgene Corp.'s stock edged 0.48% lower, to close the day at
$117.04. The stock recorded a trading
volume of 3.52 million shares, below its three months average
volume of 4.93 million shares. Over the last one month and since
the start of this year, Celgene Corp.'s shares have gained 3.23%
and 4.63%, respectively. However, the stock has lost 1.73% in the
previous three months. The company's shares are trading 1.75% below
their 200-day moving average. Additionally, Celgene Corp. traded at
a PE ratio of 44.33 and has a Relative Strength Index (RSI) of
40.44. Sign up and read the free notes on CELG at:
https://www.erionline.net/CELG.pdf
On Wednesday, shares in Ariad Pharmaceuticals Inc. recorded a
trading volume of 2.01 million shares, lower than their three
months average volume of 4.32 million shares. The stock ended the
day 1.91% lower at $7.18. Although,
Ariad Pharmaceuticals Inc.'s stock has lost 17.38% in the previous
three months, it has advanced 11.49% in the last one month and
4.51% on YTD basis. The company is trading below its 50-day and
200-day moving averages by 8.19% and 9.37%, respectively.
Furthermore, shares of Ariad Pharmaceuticals Inc. have an RSI of
42.69. The complimentary notes on ARIA can be downloaded in PDF
format at:
https://www.erionline.net/ARIA.pdf
ImmunoGen Inc.'s stock lost 4.51%, to close Wednesday's session
at $11.44. The stock recorded a
trading volume of 1.79 million shares, above its three months
average volume of 1.33 million shares. Over the last one month and
the previous three months, ImmunoGen Inc.'s shares have declined
10.56% and 20.56%, respectively. However, the stock has surged
87.54% since the start of this year. The company is trading 6.16%
above its 200-day moving average. Furthermore, ImmunoGen Inc.'s
stock has an RSI of 36.27. Register for free on Equity Research
Institute and access the latest research on IMGN at:
https://www.erionline.net/IMGN.pdf
BioDelivery Sciences International Inc.'s stock finished
Wednesday's session 5.03% lower at $6.61. A total of 1.88 million shares were
traded, which was above its three months average volume of 1.28
million shares. Over the previous three months and since the
beginning of 2015, BioDelivery Sciences International Inc.'s shares
have declined 21.59% and 45.01%, respectively. However, the stock
has gained 6.44% in the last one month. The company's shares are
trading below their 50-day and 200-day moving averages by 10.94%
and 35.55%, respectively. BioDelivery Sciences International Inc.'s
stock has an RSI of 41.91. The complete research on BDSI is
available for free at:
https://www.erionline.net/BDSI.pdf
On Wednesday, shares in Esperion Therapeutics Inc. ended the
session 3.34% higher at $45.42. The
stock reported a trading volume of 1.00 million shares, below its
three months average volume of 1.22 million shares. Esperion
Therapeutics Inc.'s shares have plummeted 12.59% in the last one
month and 45.94% in the previous three months. However, the stock
has gained 12.31% on YTD basis. The company is trading 27.07% below
its 50-day moving average and 37.73% below its 200-day moving
average. Moreover, shares of Esperion Therapeutics Inc. have an RSI
of 39.09. Free in-depth research on ESPR is available at:
https://www.erionline.net/ESPR.pdf
--
About Equity Research Institute:
Equity Research Institute ("ERI") produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. ERI has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
ERI has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a third
party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the
"Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as
necessary, based on sound investment judgment and publicly
available information which is believed to be reliable. The
Reviewer and the Sponsor have not performed any independent
investigations or forensic audits to validate the information
herein. Unless otherwise noted, any content outside of this
document has no association with the Author, the Reviewer, or the
Sponsor (collectively referred to as the "Production Team") in any
way. The Production Team is compensated on a fixed monthly basis
and do not hold any positions of interest in any of the securities
mentioned herein.
NO WARRANTY
ERI, the Author, the Reviewer and the Sponsor (collectively
referred to as the "Publishers") are not responsible for any error
which may be occasioned at the time of printing of this document or
any error, mistake or shortcoming. No liability is accepted by the
Publishers whatsoever for any direct, indirect or consequential
loss arising from the use of this document. The Publishers
expressly disclaim any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Additionally, the
Publishers do not (1) guarantee the accuracy, timeliness,
completeness or correct sequencing of the information, or (2)
warrant any results from use of the information. The included
information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither ERI nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
http://www.erionline.net.
RESTRICTIONS
ERI is not available to residents of Belarus, Cuba, Canada,
Iran, North Korea, Sudan, Syria
or Somalia.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE www.erionline.net